CD274 and neoplasm: A prior study of TMB across tumor types showed that 83% of patients with MSI‐H status had TMB‐H; however, only 16% of TMB‐H patients had MSI‐H status.48 Given that MSI‐H, TMB‐H and PD‐L1 expression often do not cooccur, it is not surprising that the current study often found distinct relationships between each of these three immunotherapy markers and the protein markers.